KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Xenon Pharmaceuticals (XENE) over the last 11 years, with Q1 2025 value amounting to 856.95%.

  • Xenon Pharmaceuticals' EBITDA Margin changed N/A to 856.95% in Q1 2025 from the same period last year, while for Sep 2025 it was 4213.83%, marking a year-over-year change of. This contributed to the annual value of 1368.91% for FY2022, which is 9404600.0% down from last year.
  • Latest data reveals that Xenon Pharmaceuticals reported EBITDA Margin of 856.95% as of Q1 2025.
  • Over the past 5 years, Xenon Pharmaceuticals' EBITDA Margin peaked at 198.14% during Q1 2022, and registered a low of 29632.58% during Q3 2022.
  • Over the past 3 years, Xenon Pharmaceuticals' median EBITDA Margin value was 760.8% (recorded in 2025), while the average stood at 4861.85%.
  • Examining YoY changes over the last 5 years, Xenon Pharmaceuticals' EBITDA Margin showed a top increase of 1703500bps in 2022 and a maximum decrease of -292859500bps in 2022.
  • Over the past 3 years, Xenon Pharmaceuticals' EBITDA Margin (Quarter) stood at 664.65% in 2021, then crashed by -4358bps to 29632.58% in 2022, then surged by 97bps to 856.95% in 2025.
  • Its EBITDA Margin stands at 856.95% for Q1 2025, versus 29632.58% for Q3 2022 and 5813.06% for Q2 2022.